The European Scientific foundation for Laboratory Hemato Oncology (ESLHO) is a scientifically independent foundation that promotes innovation, standardization, quality control and education of laboratory diagnostics focused on lymphoid malignancies, together with the associated consortia EuroClonality, EuroFlow and EuroMRD.
Every year in November, ESLHO organizes a scientific symposium. During this event, speakers from all over the world share their knowledge and talk about the latest results from research projects related to laboratory diagnostics for lymphoid malignancies.
EU Regulation on in vitro diagnostic medical devices (IVDR)
The IVDR, which will regulate all in vitro diagnostic medical devices (IVDs) from May 2022 onwards, will have a major impact on IVD manufacturers as well as diagnostic laboratories. To aid laboratories from the ESLHO networks with their preparations for the IVDR, including compliance to the IVDR requirements for in-house devices, ESLHO provides information and support in the form of lectures, symposia, publications and a dedicated web page.
ESLHO is a Specialized Working Group of the European Hematology Association. At the annual EHA Congress, ESLHO presents its innovations in the special EHA-SWG sessions.
‘Winning the poster prize is really something special’
Just as last year, Julia Böck from the University of Würzburg presented a poster at ESLHO symposium which took place last month in Salamanca, Spain. Last year she won the Special Poster Prize awarded by ESLHO. The winner is chosen after they have the opportunity to present and discuss their work to the public during a prolonged poster session at lunchtime. “I was positively surprised to win the prize last year. During the session I already received a lot of positive feedback which also led to interesting discussions. This was very helpful. When you are working on such a study, ours was about NGS panels for T-Cell diagnosis, one looks at it in a certain way. Those new insights made us rethink the way we group the data. That was very helpful.
For me the major honour came from the fact that the winner was chosen by the public, which is very knowledgeable at the ESLHO Symposium. This made it extra special to me. Being part of EuroClonality has brought so many new insights. The group is relatively small and it feels very familiar. This makes meeting the people and talking about different issues really easy. For example, discussing the results of the EQA is especially interesting to me. I personally don’t do the testing so often, and these sessions make things much clearer to me. Every time I come I learn something new.”
EQA Schemes opened for registration
External Quality Assessment schemes are a tool for clinical laboratories to evaluate and manage the quality of laboratory practice with the support of an independent party.
The ESLHO EQA schemes help diagnostic laboratories worldwide to achieve the highest performance and quality. IG/TR clonality testing, MRD and flow cytometric immunophenotyping have become essential for an accurate diagnosis, classification, and disease monitoring in hemato-oncology. The EQA schemes answer the need for evaluation of performance, continuous improvement and education, and standardization/comparability of measurements in different diagnostic centers for these In Vitro Diagnostic tests.
Registration for the 2024 rounds of the EQA schemes of EuroClonality, EuroMRD and EuroFlow is now open. Do you wish to participate or want to learn more? Go to: eqascheme.org (IG/TR Clonality), www.euromrd.org (MRD) and/or www.euroflow.org/qa (FLOW) 📷 credit: Biomedical Quality Assurance Research Unit of the KU Leuven.
ESLHO Symposium in Salamanca well-attended
The annual ESLHO week took place from 5 to 12 November. In the beautiful historic city of Salamanca, Spain, participants from all three ESLHO consortia, EuroFlow, EuroClonality and EuroMRD, came to the Hospedaria Fonseca to present and discuss the status and results of their joint scientific research and EQA programs. The highlight of the week was the 12th ESLHO Symposium titled 'New Developments in flow cytometry, immunogenetics and MRD assessment', with speakers from all over the world. During the day there was a special Poster Session where visitors could stay informed of the latest developments of the laboratories involved and the entrants could win the Special Poster Prize. This year's winner was Kerry Wall with her poster entitled: ‘Molecular residual disease analysis in a high throughput laboratory setting: Can automated DNA extraction of total white blood cells effectively substitute for DNA obtained via mononuclear cell separation?’